SYDNEY — Shares of 4DMedical Ltd surged 9.77% on Wednesday to close at $4.72, extending one of the most remarkable rallies on the Australian Securities Exchange this year as the respiratory imaging technology company continued to benefit from expanding hospital adoption of its flagship diagnostic software in the United States. The company markets the technology through a software-as-a-service model, allowing hospitals to integrate the platform with existing CT scanning infrastructure rather than purchase new equipment. Commercial Momentum BuildingThe stock's rally in recent sessions has been underpinned by a series of commercial and regulatory milestones. In May, 4DMedical secured a three-year contract with Arizona-based SimonMed Imaging, under which the diagnostic imaging network will deploy the company's CT:VQ and LDAf cardiopulmonary analysis solutions across its network of facilities. A Volatile YearDespite the extraordinary 12-month gain, 4DMedical's share price has been characterized by dramatic swings in both directions throughout 2026.